Project Grant R43CA310238
- Cooler Heads Care, Inc. was awarded a $632,981.28 Project Grant from the National Cancer Institute's Cancer Cause and Prevention Research program (CFDA 93.393) to develop a portable, patient-administered scalp cooling device and smartphone application. The goal is to reduce barriers to scalp cooling access for chemotherapy patients experiencing hair loss. Cooler Heads will develop training materials and conduct usability testing to demonstrate patients can self-administer the scalp cooling...
- This Project Grant award from the National Cancer Institute (NCI), under the Federal Assistance Listings program CFDA 93.395 Cancer Treatment Research, provides $406,500.00 to support the development of a novel, low-cost, single-use trans-nasal cryotherapy device for esophageal cancer treatment in low-resource settings. The project aims to design and validate a functional prototype of this first-of-its-kind device, which would enable unsedated cryoablation procedures to be administered through...
- This federal Project Grant award of $374,095 from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), aims to develop a device that uses an infrared laser to enable local delivery of a high dose of chemotherapy to the surgical cavity after tumor resection. The technology employs thermosensitive liposomal nanoparticles encapsulating chemotherapy agents that...
- This $275,000 Small Business Technology Transfer (STTR) Phase I grant from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships program) was awarded to Oncoblaze LLC to develop a novel device for targeted delivery of chemotherapy agents to tissue surrounding surgically removed tumors. The project aims to address the issue of tumor recurrence after cancer surgery, which affects 30-40% of patients for certain cancers. The device uses an infrared laser to heat...
- This $375,134 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a novel approach for reducing the off-target accumulation of chemotherapeutic nanomedicines. The key objectives are to characterize an innate immune response that can be leveraged to limit nanoparticle deposition in healthy tissues, thereby enhancing delivery to tumors and improving the efficacy of chemotherapy. The 5-year project, starting on March 1, 2025,...
- This federal Project Grant award of $226,704 from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) supports research to develop a novel nanoparticle heating system for cancer therapy. The project aims to use low-frequency ferromagnetic resonance to efficiently heat magnetic nanoparticles and deposit energy into cancer cells, while minimizing heating of surrounding normal tissue. The award was granted to the Dartmouth-Hitchcock Clinic, a non-profit...
- This $391,325 federal Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports the development of non-invasive, quantitative microscopic biomarkers to assess chemotherapy-induced peripheral neuropathy (CIPN) in cancer patients. The principal investigator, Dr. Kang from the University of Arizona, is leading the effort to utilize portable confocal microscopy (PCM) technology to visualize changes in Meissner's corpuscles, which are nerve...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,379,442 to Embiosys Inc. from September 2025 to August 2027 to develop and evaluate a novel wearable device that delivers induced electric field (IEF) therapy for the treatment of triple-negative breast cancer (TNBC). The key product being developed is a wearable, washable garment (camisole/tank-top) that can deliver low-intensity, intermediate frequency electromagnetic radiation...
- The federal Project Grant award of $247,660 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is supporting research to characterize the microenvironment of autologous fat grafts resulting from different intraoperative processing techniques. This study aims to compare outcomes, including volume retention, between three fat grafting devices that process the lipoaspirate in different ways before injection. The project will utilize fat samples collected from patients...
- The National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research CFDA program (93.394), has awarded a $3,036,844 Project Grant to the University of Southern California (USC) to develop a wireless, wearable thermo-activator device for precise, localized control of chimeric antigen receptor (CAR) T cell therapy in solid tumors. The project aims to overcome limitations of current MRI-guided focused ultrasound approaches by creating a flexible, portable system that can remotely...
This $305,040 federal Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) was awarded to Rush River Research Corp, a woman-owned small business, to develop and validate a next-generation scalp cooling device using solid-state thermoelectric cooling technology. This novel device is designed to mitigate chemotherapy-induced alopecia, a common and distressing side effect of cancer treatment that impacts approximately 65% of patients. The goal is to create a fluid-free, fully portable scalp cooling cap that provides precise, sustained cooling without external equipment, enhancing patient comfort and mobility. This project aims to improve quality of life for cancer patients receiving chemotherapy by providing a more effective, affordable, and patient-friendly solution for preventing chemotherapy-induced hair loss, and expanding access to underserved communities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $305.0k | 9/8/25 |